News

News

08 January 2019: Sysmex Launches New Products in the Haemostasis Field: Automated Blood Coagulation Analysers CN-6000 and CN-3000

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces the launch of its next-generation analysers in the haemostasis field, the Automated Blood Coagulation Analysers CN-6000 and CN-3000. Sysmex is a leading company in blood coagulation analysers. Through the launch of the CN-6000 and CN-3000, Sysmex aims to further enhance levels of productivity, reliability, and operability, in turn responding to diverse customer needs and contributing to even better efficiency and higher quality in the field of haemostasis.

06 January 2019: Sysmex Launches Flow FISH Testing System for Research Applications That Utilises Imaging FCM Technology to Automate FISH Testing

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) will launch the Imaging Flow Cytometer MI-1000 and related software MI FISH Master as a system. This system utilizes imaging FCM technology1 to automate FISH testing2 for determining chromosomal abnormalities in circulating cells. By pursuing the verification of utility in the research market of automated FISH testing using the system, Sysmex aims to establish a basis for the clinical use of flow FISH testing at an early stage, as well as to increase the efficiency of and standardize FISH testing.

04 December 2018: Sysmex Wins Encouragement Prize for First Time in 6th WICI Japan Award for Excellence in Integrated Reporting

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) received the Integrated Reporting Encouragement Prize in the 6th WICI Japan Award for Excellence in Integrated Reporting. This is the first time that Sysmex has won this award.

04 December 2018: With a View to New Value Creation, Sysmex Launches a Research Assay Service for HDL Function Measurement

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) will provide high-density lipoprotein (HDL) function measurement (for research) as a research assay service, leveraging the Company’s measurement platform and assay-related expertise. Through this service, Sysmex aims to contribute toward the creation of new methods for diagnosing and treating atherosclerosis-related diseases.

29 November 2018: Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialisation

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and MolecularMD Corporation (HQ: Portland, Oregon, United States; President and CEO: Dan Snyder), a molecular diagnostics company, announced today a master collaboration agreement targeting the challenges in current and future companion diagnostics (CDx)* development and commercialization needed to accelerate precision medicine.

13 November 2018: Sysmex Launches Single Molecule Fluorescence Microscope HM-1000 for Research Use

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has launched a super-resolution fluorescence microscope, the HM-1000 single-molecule fluorescence microscope, for research use. Employing super-resolution imaging technology, the HM-1000 achieves high spatial resolution1 (of less than 40nm), going beyond the limits of conventional fluorescence microscopes. As a result, the HM-1000 can be used for minute observation, such as the morphology of tiny proteins that exist within cells and the distribution of genes. Sysmex expects the HM-1000 to contribute toward effective R&D related to next-generation therapeutic drugs and diagnostic methods that will lead toward the realization of personalized medicine, as well as to developments in cellular biology.

24 October 2018: Strengthening Our Global R&D Structure to Foster Early-Stage Innovation

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) has decided to reinforce its global R&D structure to accelerate R&D that leverages local characteristics. We aim to foster early-stage innovation through the acquisition of opportunities to participate in projects headed by national and regional government entities, proactive recruitment of local R&D personnel, and enhanced collaboration with overseas subsidiaries. To begin, we incorporated our R&D Center in Europe. We believe this move will enhance its agility, accelerating such multifaceted R&D activities as technology searches and development in Europe, as well as supporting market launches.

18 September 2018: Sysmex Selected for Inclusion in the Dow Jones Sustainability World Index for the Third Consecutive Year

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces that it has been selected for inclusion in the Dow Jones Sustainability World Index (DJSI World), a leading global index of ESG investment, for the third consecutive year.

30 August 2018: Sysmex, Toppan Printing, and RIKEN GENESIS Commence Launch of Fully Automated System (Research Use Only) to Detect Gene Mutations in Cancer Tissue

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Toppan Printing Co., Ltd. (HQ: Tokyo, Japan; President & Representative Director: Shingo Kaneko) and RIKEN GENESIS Co., Ltd. (HQ: Tokyo, Japan; President & CEO; Naoto Kondo) have jointly developed the LW-100 Gene Measurement Analyzer (research use only) and a group of related reagents as a system to fully automate testing to detect gene mutations in cancer tissue.

23 August 2018: Sysmex Partec’s CyFlow™ Counter System, a System to Test for CD4+ Lymphocytes, Receives WHO Prequalification

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) provides notice that the CyFlow™ Counter System (CyFlow™ Counter with CD4 easy count kit and CD4% easy count kit), developed and produced by its subsidiary Sysmex Partec (“Partec”), has received WHO prequalification. This testing system helps diagnose and monitor the immune status of people infected with HIV by checking CD4 in human blood samples. This marks the first time a Sysmex Group product has received WHO prequalification.